EXPRES2ION BIOTECH HLDG
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor. It is also developing ES2B-I002, a cytomegalovirus vac… Read more
EXPRES2ION BIOTECH HLDG (5JD) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, EXPRES2ION BIOTECH HLDG (5JD) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
EXPRES2ION BIOTECH HLDG - Net Assets Trend (None–None)
This chart illustrates how EXPRES2ION BIOTECH HLDG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for EXPRES2ION BIOTECH HLDG (None–None)
The table below shows the annual net assets of EXPRES2ION BIOTECH HLDG from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to EXPRES2ION BIOTECH HLDG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
EXPRES2ION BIOTECH HLDG Competitors by Market Cap
The table below lists competitors of EXPRES2ION BIOTECH HLDG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VISHAY INTERTECHNOL
BE:VHY
|
$146.52K |
|
IA Invest FormueFyn Skandi+
CO:IAIFFS
|
$146.69K |
|
Bellerophon Therapeutics Inc
PINK:BLPH
|
$146.79K |
|
The China Fund Inc
F:CHN
|
$146.84K |
|
QcX Gold Corp
PINK:QCXGF
|
$146.32K |
|
Axon Partners Group S.A.
MC:APG
|
$146.29K |
|
Sociallite US AB (publ)
F:8450
|
$146.23K |
|
BASLER
HM:BSL
|
$146.22K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EXPRES2ION BIOTECH HLDG's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares EXPRES2ION BIOTECH HLDG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently EXPRES2ION BIOTECH HLDG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares EXPRES2ION BIOTECH HLDG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EXPRES2ION BIOTECH HLDG (5JD) | €- | N/A | N/A | $146.33K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |